University of Colorado Cancer Center study shows that pre-programmed stem cell demise allows cancer after radiation, and that NOTCH signaling can restore stem cell function.
University of Colorado Cancer Center study published today in the journal Aging shows that in addition to DNA damage, cancer depends on the slow degradation of tissue that allows cancer cells to out-compete healthy cells.
"We're on the cusp of a major revolution in the way we treat breast cancer," says University of Colorado Cancer Center investigator, Jennifer Richer, PhD.
University of Colorado Cancer Center study being presented at the San Antonio Breast Cancer Symposium shows that triple negative breast cancer cells process tryptophan to promote survival while traveling through the body in order to seed new tumor sites.
"Alcohol damages cells and resveratrol kills damaged cells," says Robert Sclafani, PhD.
Experimental anti-cancer drugs PF-04691502 and PD-0325901 excel in tests against colorectal cancer models and enter phase 1 clinical trial.
University of Colorado Cancer Center study shows "extremely promising” early phase 1 clinical trial results for the investigational drug AG-120 against the subset of patients with acute myeloid leukemia (AML) harboring mutations in the gene IDH.
A University of Colorado Cancer Center study published online this week in the journal Molecular Cancer Therapeutics reports anti-cancer activity in 10 out of 11 patient tumor samples grown in mice and treated with the experimental drug TAK-733, a small molecule inhibitor of MEK1/2.
University of Colorado Cancer Center study shows that IL-37 regulates immune sensitivity across disease types
Vitamin D upregulates the gene GDF-15. Study shows that GDF-15 is lost in prostate cancer driven by inflammation.
Study highlights need to monitor disease in developing countries even when burden of diseases is low.
University of Colorado Cancer Center researchers report 72 percent response rate with 19.2 month progression-free survival.
Cancer subtypes are like rare diseases; a new kind of clinical trial uses Dr. Google to find enough needles in enough haystacks to test drug ponatinib against FGFR positive lung cancer.
Computer model, COXEN, matches cancer genetics to best treatment. Currently in national clinical trial in bladder cancer.
A University of Colorado Cancer Center study recently published in Nucleic Acids Research describes a database named multiMiR, the most comprehensive database collecting information about microRNAs and their targets.
University of Colorado Cancer Center study shows that by taking into account the real-world constraints of the systems in which providers deliver care and patients receive it, researchers can help speed results, cut costs, and increase chances that recommendations from their findings will be implemented.
A University of Colorado Cancer Center study published in the Dermatology Online Journal shows that YouTube also allows researchers, journals, and health advocates to connect directly with the public on topics of skin cancer and prevention.
Results presented today at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) and June 6 at the European Association of Palliative Care Research Conference show that stopping statins for cholesterol management in the late stages of cancer or other terminal illnesses may offer quality-of-life and even life-extending benefits.
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
Research presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2014 used a newly designed test for K:B fusion to show that point mutations lead to a more dangerous form of the disease than does K:B fusion.
A study published June 1 in the journal Nature Biotechnology describes the results of an open challenge to predict which breast cancer cell lines will respond to which drugs, based only on the sum of cells’ genomic data.
An education session presented today at the American Society for Clinical Oncology (ASCO) Annual Meeting 2014 details the challenges of collaboration between oncologists and pathologists in the context of molecular testing patient tumor samples.
Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present.
At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs).
A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation.
A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity.
A study recently published in the journal Bioinformatics describes a new database and pattern-matching algorithm that allows researchers to evaluate rational drugs and drug combinations, and also recommends a new drug combination to treat drug-resistant non-small cell lung cancer.
University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.
"If our endgame is to modify their behavior, we need to tailor our message in the right way and in this case the right way is by highlighting consequences to appearance rather than health," says April W. Armstrong, PhD, MPH.
"It may be that childhood obesity changes the way the whole metabolism is working – and changes it during a critical developmental time frame,” says Kristen Nadeau, MD, investigator at the University of Colorado Cancer Center.
After a child’s stem cell transplant, parents feel increased distress at the time of the procedure, but eventually recover to normal levels of adjustment.
University of Colorado Cancer Center study shows common locations of prostate cancers missed by ultrasound-guided biopsy.
CU Cancer Center study: bladder and lung cancers are marked by shared differences in the genetics that control the cell cycle, with diagnostic, prognostic and treatment implications.
Study: patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease.
A University of Colorado Cancer Center study, recently published in the journal Oncogene, shows that downstream from the oncogenic fusion of genes EWS with FLI1 is a signaling chain that includes microRNA-22 and the gene KDM3A. By targeting these links, researchers hope to break this cancer-causing chain.
Addition of Bevacizumab to the existing standard of care was safe and showed promising overall results. The 2- and 3- year overall survival rates were 89.8 percent and 80.2 percent, respectively.
A CU Cancer Center study published today in the journal Stem Cells shows that progenitor cells that create dangerous, muscle-invasive bladder cancer are different than the progenitor cells that create non-muscle invasive bladder cancer. Though these two cancers grow at the same site, they are different diseases.
A University of Colorado Cancer Center study shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.
New tool allows doctors to recognize patients at highest mortality risk, matching treatments to values and health goals.
Controlled, lab studies of grape seed extract (GSE) show anti-cancer activity without toxicity to healthy cells
A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one of the most commonly used clinical methods.
"If a journal wants to educate people, this is a way to do it," says Robert Dellavalle, MD, PhD, MSPH, investigator at the CU Cancer Center and associate professor of dermatology at the University of Colorado School of Medicine.
Moyed Miften, PhD, and CU Cancer Center colleagues show that mis-positioning of endorectal balloon during prostate cancer radiation may affect treatment success
University of Colorado Cancer Center investigator, Rachel Rabinovitch, MD, shows that mastectomy is more used and radiation is less used in male compared to female breast cancer.
A University of Colorado Cancer Center study published in the journal PLoS One shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by the drug, to related growth factors in including VEGF-C, VEGF-D and placental growth factor. This change to new growth-factor dependence may allow colorectal cancer to push past bevacizumab’s blockage of VEGF-A to continue to drive tumor growth.
University of Colorado Cancer Center study shows that breast cancer cell growth, motility and aggression is promoted by excess glucose, as experienced by patients with diabetes and metabolic syndrome. Patients with high glucose may require higher doses of the drug metformin to achieve the same anti-cancer activity as patients with normal glucose levels.
A decade of work at the University of Colorado Cancer Center puts androgen alongside estrogen, progesterone and HER2 as a major cause of breast cancer.
A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug.
Study shows that wait times for cancer care at V.A. hospitals jumped 78 percent from 1998-2008, but is more careful care worth the wait?
A recent study by members of the Children’s Oncology Group reports results of a large trial showing that children whose leukemia cells have amplification of a portion of chromosome 21 may require more aggressive treatment for Acute Lymphoblastic Leukemia (ALL) than children without this gene amplification.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right